OptiNoseOPTN
OPTN
About: OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Employees: 132
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
33% less capital invested
Capital invested by funds: $72.7M [Q3] → $48.7M (-$24M) [Q4]
40% less funds holding
Funds holding: 65 [Q3] → 39 (-26) [Q4]
67.34% less ownership
Funds ownership: 72.18% [Q3] → 4.84% (-67.34%) [Q4]
89% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 28
97% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 35
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
2%
downside
Avg. target
$9
2%
downside
High target
$9
2%
downside
3 analyst ratings
0 positive
0%
3 neutral
100%
0 negative
0%
Piper Sandler David Amsellem 57% 1-year accuracy 20 / 35 met price target | 2%downside $9 | Neutral Downgraded | 21 Mar 2025 |
HC Wainwright & Co. Matthew Caufield 39% 1-year accuracy 23 / 59 met price target | 2%downside $9 | Neutral Downgraded | 21 Mar 2025 |
Lake Street Thomas Flaten 44% 1-year accuracy 4 / 9 met price target | 2%downside $9 | Hold Downgraded | 20 Mar 2025 |
Financial journalist opinion
Based on 9 articles about OPTN published over the past 30 days
Neutral
Business Wire
2 days ago
OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of OptiNose, Inc. (NasdaqGS: OPTN) to Paratek Pharmaceuticals. Under the terms of the proposed transaction, shareholders of OptiNose will receive $9.00 per share in cash, plus up to $5.00 per share in contingent value rights payable in the event that certain net revenue milestones are achieved by XHANC.
Positive
Zacks Investment Research
2 days ago
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.
Neutral
GlobeNewsWire
2 days ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders
NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Neutral
PRNewsWire
3 days ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTN
NEW YORK , March 20, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating OptiNose, Inc. (NASDAQ: OPTN ), relating to the proposed merger with Paratek Pharmaceuticals.
Neutral
GlobeNewsWire
3 days ago
OPTN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of OptiNose, to Paratek Pharmaceuticals
MONSEY, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of OptiNose, Inc. (Nasdaq: OPTN) (“OptiNose”) to Paratek Pharmaceuticals (“Paratek”) for $9.00 per share in cash, plus a contingent value right (“CVR”) worth $5.00 per share payable in the event that certain net revenue milestones are achieved by OptiNose's flagship drug, XHANCE.
Neutral
Business Wire
3 days ago
OPTN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Optinose, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Optinose, Inc. (NASDAQ: OPTN) to Paratek Pharmaceuticals is fair to Optinose shareholders. Under the terms of the proposed transaction, Paratek will acquire Optinose for $9.00 per share in cash, plus up to $5.00 per share in contingent value rights payable in the event that certain net revenue milestones are achieved by XHANCE. Halper Sadeh encourages Optinose shareholders to click her.
Neutral
Business Wire
3 days ago
Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Optinose (NASDAQ:OPTN) for possible breaches of fiduciary duty and other violations of law in its transaction with Paratek. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Optinose shareholders will receive only up to $14 per share, but this includes the payment of contingent va.
Neutral
GlobeNewsWire
3 days ago
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time.
Neutral
GlobeNewsWire
3 days ago
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10 ‑ million ‑ patient market Acquisition advances Paratek's vision to become a multi-product company focused on innovative specialty therapies Total transaction value of up to ~$330 million Potential consideration of up to $14 per share, including upfront consideration of $9 per share, representing a 50% premium to Optinose's closing trading price on March 19, 2025 BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, including its approved product XHANCE ® (fluticasone propionate).
Neutral
GlobeNewsWire
2 months ago
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%
Charts implemented using Lightweight Charts™